Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
作者： Tao Song , Wei Yu , Shi-Xiu Wu
DOI: 10.7314/APJCP.2014.15.1.205
关键词:
摘要: The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages over traditional treatment strategies in patients with non-small cell lung cancer (NSCLC), but unfortunately we to face the situation that most still fail respond long term despite initially good control. Up now, mechanism acquired resistance has not been fully clarified. Herein, sought compile available clinical reports hope better understanding subsequent choices, particularly on whether restoring after a drug holiday or switching another EGFR-TKI is option failure one kind EGFR-TKI.
koreascience.or.kr参考文章(66)
Yong-feng Yu, Zheng-bo Song, Shun Lu, Zhi-wei Chen, Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chinese Medical Journal. ,vol. 124, pp. 2279- ,(2011)
Seiji Yano,, Emiko Nakataki, Shinsaku Ohtsuka, Mami Inayama, Hideki Tomimoto, Nobutaka Edakuni, Soji Kakiuchi, Naoki Nishikubo, Hiroaki Muguruma, Saburo Sone, Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology Research. ,vol. 15, pp. 107- 111 ,(2005) , 10.3727/096504005775082020
Daxian Luo, Meijuan Huang, Xinxing Zhang, Min Yu, Bingwen Zou, Yanying Li, Jianlin Long, Jin Wang, Feng Peng, Yong Xu, Lu Li, Li Ren, Mei Hou, You Lu, Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case–control study Thoracic Cancer. ,vol. 3, pp. 27- 33 ,(2012) , 10.1111/J.1759-7714.2011.00087.X
Kazuhiro Asami, Masaaki Kawahara, Shinji Atagi, Tomoya Kawaguchi, Kyoichi Okishio, Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib Lung Cancer. ,vol. 73, pp. 211- 216 ,(2011) , 10.1016/J.LUNGCAN.2010.12.014
Tomonobu Koizumi, Toshihiko Agatsuma, Kayoko Ikegami, Toshiro Suzuki, Takashi Kobayashi, Shintaro Kanda, Sumiko Yoshikawa, Keishi Kubo, Takayuki Shiina, Keiichirou Takasuna, Akemi Matsuo, Muneharu Hayasaka, Miwa Morikawa, Shingo Ameshima, Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer Who Previously Responded to Gefitinib Clinical Lung Cancer. ,vol. 13, pp. 458- 463 ,(2012) , 10.1016/J.CLLC.2012.01.006
Xiao-Dong Li, Yi-Ting Geng, Chang-Ping Wu, Hua Shen, Jing Sun, Yong-Qian Shu, Yong-Mei Yin, Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie. ,vol. 33, pp. 466- 469 ,(2010) , 10.1159/000319109
Akihiro Yoshimoto, Kanako Inuzuka, Toshiyuki Kita, Atsuhiro Kawashima, Kazuo Kasahara, Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. The American Journal of the Medical Sciences. ,vol. 333, pp. 221- 225 ,(2007) , 10.1097/MAJ.0B013E31803B8ACB
Y Ohsaki, S Tanno, Y Fujita, E Toyoshima, S Fujiuchi, Y Nishigaki, S Ishida, A Nagase, N Miyokawa, S Hirata, K Kikuchi, Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncology Reports. ,vol. 7, pp. 603- 610 ,(2000) , 10.3892/OR.7.3.603
Takehito Shukuya, Toshiaki Takahashi, Tateaki Naito, Rieko Kaira, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Haruyasu Murakami, Hideyuki Harada, Koichi Mitsuya, Masahiro Endo, Yoko Nakasu, Kazuhisa Takahashi, Nobuyuki Yamamoto, Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer. ,vol. 74, pp. 457- 461 ,(2011) , 10.1016/J.LUNGCAN.2011.04.007
Francesco Grossi, Erika Rijavec, Maria Giovanna Dal Bello, Carlotta Defferrari, Annalisa Brianti, Giulia Barletta, Carlo Genova, Carmelina Murolo, Maurizio Cosso, Gabriella Fontanini, Laura Boldrini, Mauro Truini, Paolo Pronzato, The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemotherapy and Pharmacology. ,vol. 69, pp. 1407- 1412 ,(2012) , 10.1007/S00280-012-1848-4